右旋酮洛芬结构式
|
常用名 | 右旋酮洛芬 | 英文名 | S-(+)-Ketoprofen |
|---|---|---|---|---|
| CAS号 | 22161-81-5 | 分子量 | 254.281 | |
| 密度 | 1.2±0.1 g/cm3 | 沸点 | 431.3±28.0 °C at 760 mmHg | |
| 分子式 | C16H14O3 | 熔点 | 75-78ºC(lit.) | |
| MSDS | 中文版 美版 | 闪点 | 228.8±20.5 °C | |
| 符号 |
GHS06, GHS09 |
信号词 | Danger |
|
Hologram QSAR model for the prediction of human oral bioavailability.
Bioorg. Med. Chem. 15 , 7738-45, (2007) A drug intended for use in humans should have an ideal balance of pharmacokinetics and safety, as well as potency and selectivity. Unfavorable pharmacokinetics can negatively affect the clinical development of many otherwise promising drug candidates. A varie... |
|
|
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
J. Med. Chem. 48 , 4312-31, (2005) The CXC chemokine CXCL8/IL-8 plays a major role in the activation and recruitment of polymorphonuclear (PMN) cells at inflammatory sites. CXCL8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR... |
|
|
Scope of partial least-squares regression applied to the enantiomeric composition determination of ketoprofen from strongly overlapped chromatographic profiles.
J. Sep. Sci. 38 , 2423-30, (2015) Valuable quantitative information could be obtained from strongly overlapped chromatographic profiles of two enantiomers by using proper chemometric methods. Complete separation profiles where the peaks are fully resolved are difficult to achieve in chiral se... |
|
|
Structure-activity relationships and cancer-cell selective toxicity of novel inhibitors of glioma-associated oncogene homologue 1 (Gli1) mediated transcription.
J. Med. Chem. 52 , 4277, (2009) We report novel inhibitors of Gli1-mediated transcription as potential anticancer agents. Focused chemical libraries were designed and assessed for inhibition of functional cell-based Gli1-mediated transcription and selective toxicity toward cancer cells. The... |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2026 ChemSrc All Rights Reserved
